KZIA - ノボゲン （Kazia Therapeutics Limited） ノボゲンKZIAのチャート
KZIAの企業情報
| symbol | KZIA |
|---|---|
| 会社名 | Kazia Therapeutics Ltd （ノボゲン） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Miscellaneous |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 カジア・セラピュティクス(Kazia Therapeutics Limited)（旧名:Novogen Limited）はがん治療の開発に従事するオンコロジーバイオテクノロジー会社である。同社は主に医薬品の研究・開発を行う。同社はスーパーベンゾピラン（SBP）技術および抗トロポミオシン（ATM）2つの医薬プラットフォームを有する。そのプラットフォームは多様な腫瘍学的適応症にわたり各種の薬物候補を産生する。同社の製品候補には、Cantrixil（TRX-E-002-1）、Anisina（ATM-3507）、Trilexium（TRX-E-009-1）がある。Cantrixilの適応症は卵巣がんであり、Trilexiumの適応症はびまん性真性中枢神経膠腫（DIPG）である。Anisinaの最初の標的小児適応症は神経芽腫である。CantrixilはSBP技術から生まれたリード開発候補者である。Anisinaは、癌細胞のアクチン細胞骨格を標的とする化学療法へのアプローチである。Trilexium（TRX-E-009-1）は、SBPの第2候補薬候補である。 ノボゲンはオ―ストラリアの製薬会社。主に、がんや更年期障害などの治療薬の開発に従事。原子や化学構成成分を使用してベンゾピラン分子骨格に基づく化合物を構築する。ス―パ―ベンゾピランの搾取の早期段階にある。製薬候補の「Trilexium」は、卵巣がんと多形性膠芽腫を対象にした治療薬である。 |
| 本社所在地 | Level 5 20 George St Hornsby New South Wales 2077 AUS |
| 代表者氏名 | James B. Garner ジェームズ・B・ガーナー |
| 代表者役職名 | Chief Executive Officer Executive Director |
| 電話番号 | +61 2-9878-0088 |
| 設立年月日 | － |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 16人 |
| url | www.novogen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/kzia |
| adr_tso | 1742974 |
| EBITDA | EBITDA（百万ドル） -7.60277 |
| 終値（lastsale） | 3.1056 |
| 時価総額（marketcap） | 5412980.0544 |
| 時価総額 | 時価総額（百万ドル） 13.23090 |
| 売上高 | 売上高（百万ドル） 0.08485 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 8.99009 |
| 当期純利益 | 当期純利益（百万ドル） -4.29995 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Kazia Therapeutics Ltd (ADR) revenues decreased 52% to A$119K. Net loss decreased 43% to A$6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative expense decrease of 28% to A$5.6M (expense) Research and development expense decrease of 12% to A$9.8M (expense). |
KZIAのテクニカル分析
KZIAのニュース
Kazia Therapeutics - Reinvestment period with increased R&D focus 2023/02/01 09:34:00 Finanz Nachrichten
Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical efforts towards exploring the applicability and effic…
Trade Alert: Stephen Abolakian At Kazia Therapeutics Limited (ASX:KZA), Has Just Spent AU$1m Buying 54% More Shares 2023/01/25 20:01:32 Simply Wall St
Those following along with Kazia Therapeutics Limited ( ASX:KZA ) will no doubt be intrigued by the recent purchase of…
Kazia Therapeutics CEO talks $4.5 million capital raise 2023/01/18 16:50:00 The North America Newswire
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner speaks with Proactive after confirming a two-tranche capital raising initiative to raise A$4.5 million through placements to professional and sophisticated investors. The company''s also offer eligible shareholders the opportunity to acquire up to A$30,000 of new shares through a share purchase plan.#ProactiveInvestors #KaziaTherapeutics #asx #pharma #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews Contact Details Proactive Investors Jonathan Jackson +61 413 713 744 Jonathan@proactiveinvestors.com
EQS-News: Kazia Therapeutics Ltd: Kazia Therapeutics talks positive pre-clinical data for EVT801 2022/12/06 16:49:00 Finanz Nachrichten
EQS-News: Kazia Therapeutics Ltd Kazia Therapeutics talks positive pre-clinical data for EVT801 06.12.2022 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. C…
EQS-News: Kazia Therapeutics talks positive pre-clinical data for EVT801 2022/12/06 16:45:08 Wallstreet:Online
EQS-News: Kazia Therapeutics Ltd Kazia Therapeutics talks positive pre-clinical data for EVT801 06.12.2022 / 17:45 CET/CEST The issuer is solely responsible for the content of this announcement. Contact Details Proactive Investors Jonathan Jackson +61 413
Kazia Therapeutics provides cash outlook 2022/11/02 14:44:38 Seeking Alpha
Kazia Therapeutics (KZIA) stock rose ~3% on Wednesday after the company provided update on Q1''23 cash flow report and said that it has sufficient cash to last to end CY22.Kazia added…
Kazia Therapeutics'' (ASX:KZA) paxalisib shows positive signals against preclinical melanoma models 2022/10/27 17:00:00 The Market Herald
Kazia Therapeutics'' (ASX:KZA) paxalisib brain cancer drug has demonstrated positive efficacy signals against a range of preclinical models of metastatic melanoma.
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE 2022/09/09 12:00:00 Kwhen Finance
Investing in Kazia Therapeutics Limited (KZIA) might be a great opportunity, but the stock is a bit overvalued 2022/09/05 14:54:00 US Post News
Kazia Therapeutics Limited (NASDAQ:KZIA) closed Friday at $1.42 per share, up from $1.39 a day earlier. While Kazia Therapeutics Limited has overperformed by 2.16%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KZIA fell by -86.73%, with highs and lows ranging from $12.28 to $1.37, whereas […]
Kazia Therapeutics Limited (NASDAQ: KZIA) Stock Has Dropped -56.77% Over The Month – Is There Room For Growth? 2022/08/20 20:00:00 Marketing Sentinel
Kazia Therapeutics Limited (NASDAQ:KZIA)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 2.22. At the close of trading, the stock’s price was $1.66, to imply a decrease of -11.23% or -$0.21 in intraday trading. The KZIA share’s 52-week high remains $12.28, putting it -639.76% down since that … Kazia Therapeutics Limited (NASDAQ: KZIA) Stock Has Dropped -56.77% Over The Month – Is There Room For Growth? Read More »
Kazia Therapeutics Limited (NASDAQ: KZIA) Stock Has Dropped -56.77% Over The Month – Is There Room For Growth? 2022/08/20 20:00:00 Marketing Sentinel
Kazia Therapeutics Limited (NASDAQ:KZIA)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 2.22. At the close of trading, the stock’s price was $1.66, to imply a decrease of -11.23% or -$0.21 in intraday trading. The KZIA share’s 52-week high remains $12.28, putting it -639.76% down since that … Kazia Therapeutics Limited (NASDAQ: KZIA) Stock Has Dropped -56.77% Over The Month – Is There Room For Growth? Read More »
Kazia Therapeutics (KZIA): Ambiguity in GBM But Pipeline Still Busy - Stocks News Feed 2022/08/08 10:43:50 Stocks News Feed
LONDON, UK / ACCESSWIRE / August 8, 2022 / Kazia Therapeutics has reported that the company’s lead asset paxalisib (PI3K/mTOR inhibitor) has not graduated to Stage 2 of the Phase III GBM AGILE study in glioblastoma multiforme (GBM), as advised by the study sponsors (Global Coalition for Adaptive Research, GCAR). The study is still fully… Read More »Kazia Therapeutics (KZIA): Ambiguity in GBM But Pipeline Still Busy
Kazia Therapeutics reveals 100% response rate in interim data from brain metastases drug trial 2022/08/08 00:02:09 Small Caps
Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has presented promising new data from an ongoing phase one clinical trial of its lead drug paxalisib in combination with radiotherapy for the treatment of brain metastases. Interim data from the first stage of the study, led by Dr Jonathan Yang at the Memorial Sloan Kettering Cancer Centre […] The post Kazia Therapeutics reveals 100% response rate in interim data from brain metastases drug trial appeared first on Small Caps .
Kazia Therapeutics surges 53% on positive data from phase 1 trial of brain cancer drug 2022/08/05 13:07:02 Seeking Alpha
Kazia Therapeutics (KZIA) is trading 53% higher before the bell after the company reported positive data from a phase I trial of its drug, paxalisib, in combination with radiotherapy…
Kazia Therapeutics Limited: KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES 2022/08/05 12:52:00 Finanz Nachrichten
SYDNEY, Aug. 5, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of promising new dat…